Eli Lilly and Amazon Partner to Deliver Weight Loss Drug Zepbound Directly to Consumers

The collaboration aims to improve access to GLP-1 class weight loss drugs amidst high demand and shortages.

Eli Lilly partners with Amazon to offer home delivery of Zepbound, a weight loss drug, directly to consumers.
Zepbound, approved by the FDA at the end of 2023, has shown significant weight loss results in clinical trials.
The partnership aims to address the shortage of GLP-1 class weight loss drugs and ensure a reliable supply.
Amazon Pharmacy will also deliver other Eli Lilly medications for diabetes, obesity, and migraines through LillyDirect.
The collaboration between Eli Lilly and Amazon is part of a broader trend of pharmaceutical companies offering direct-to-consumer services.